Full Text View
Tabular View
No Study Results Posted
Related Studies
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer (IRESSA&H&N)
This study is ongoing, but not recruiting participants.
First Received: May 20, 2008   No Changes Posted
Sponsored by: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00681967
  Purpose

To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa


Condition Intervention Phase
Head and Neck Cancer
Drug: Gefitinib
Phase I

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Both cohorts overall survival (OS) local control (LC) rate at six months and at one year [ Designated as safety issue: No ]
  • Cohort 1 only time-to-recurrence (TTR) [ Designated as safety issue: No ]
  • Cohort 2 only time-to-progression (TTP). Complete Response (CR) rate time to treatment failure (TTF) [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: February 2004
Estimated Study Completion Date: March 2009
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Cohort 1: Experimental
post operative combination of gefinib and RT
Drug: Gefitinib
250 mg; oral
Cohort 2: Experimental
combination of gefitinib with RT and Chemotherapy in non operated patients
Drug: Gefitinib
250mg; oral

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Age over 18 years
  • Histologically proven squamous cell cancer of the head & neck (SCCHN)
  • Indication for postoperative Radiotherapy: pT3, pT4, pN2b, pN2c, pN3

Exclusion Criteria:

  • Hypersensitivity to ZD1839 or any of the excipients of this product
  • Tumour stage M1
  • Co-existing malignancies diagnosed within the last 5 years. Exceptions: basal cell carcinoma, cervical cancer in situ
  • Absolute neutrophil counts <1.5 x 109
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00681967

Locations
Switzerland
Research Site
Basel, Switzerland
Research Site
Bern, Switzerland
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Christoph Rochlitz, Prof Dr med University Hospital of Basel
Study Director: Madeleine Billeter, MD AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland
Study Chair: Verena Renggli AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland
  More Information

No publications provided

Responsible Party: AstraZeneca AG Switzerland ( Madeleine Billeter, MD, Medical & Regulatory Affairs Director )
Study ID Numbers: 1839IL/0525
Study First Received: May 20, 2008
Last Updated: May 20, 2008
ClinicalTrials.gov Identifier: NCT00681967     History of Changes
Health Authority: Switzerland: Swissmedic

Keywords provided by AstraZeneca:
squamous cell cancer of the head & neck
Gefitinib
IRESSA
EGFR Inhibitor
EGFR-tyrosine kinase inhibitor
Subjects with histologically proven squamous cell cancer of the head & neck
Cohort 1:qualifying for postoperative radiotherapy
(pT3, pT4, pN2b, pN2c, pN3).
Cohort 2:qualifying for definite chemoradiotherapy
(Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N;
Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity,
glottic and supraglottic larynx; Any TN1-3, T3-4 any N;
Hypopharynx: T1N1-3, T2-4 and N)

Study placed in the following topic categories:
Cisplatin
Head and Neck Neoplasms
Epidermoid Carcinoma
Tyrosine
Squamous Cell Carcinoma
Carcinoma, Squamous Cell
Protein Kinase Inhibitors
Gefitinib

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Head and Neck Neoplasms
Enzyme Inhibitors
Protein Kinase Inhibitors
Gefitinib
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 06, 2009